PA21 Safety and Efficacy in Adult Chinese Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

August 31, 2018

Primary Completion Date

August 21, 2020

Study Completion Date

August 21, 2020

Conditions
Chronic Kidney Disease Requiring Chronic DialysisHyperphosphatemia
Interventions
DRUG

PA21

sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.

DRUG

sevelamer carbonate

sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.

Trial Locations (1)

Unknown

Southern Medical University Nanfang Hospital, Guangzhou

All Listed Sponsors
lead

Vifor Fresenius Medical Care Renal Pharma

INDUSTRY

NCT03644264 - PA21 Safety and Efficacy in Adult Chinese Subjects | Biotech Hunter | Biotech Hunter